Johnson & Johnson (JNJ) is positioning itself as a strong buy amid market uncertainties, having successfully transitioned from its consumer health business to focus on innovative medicine and medtech. While the loss of exclusivity for its top-selling drug, Stelara, posed challenges, J&J has managed to maintain growth through its robust portfolio, which includes 28 products generating over $1 billion annually.
The current market climate, marked by volatility and economic concerns, has seen J&J’s shares rise 15% this year, highlighting the resilience of pharmaceutical stocks. Investors are drawn to J&J not only for its stability during downturns but also for its impressive dividend track record, boasting a yield of 2.1%—well above the S&P 500 average.
For professionals looking to bolster their portfolios, J&J’s strong fundamentals and commitment to dividend growth make it an attractive long-term investment. I recommend reading the full article for deeper insights into J&J’s strategic advantages.
Source: fool.com